Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival

• Published in: Leukemia & lymphoma Vol. 50; no. 5; pp. 741 - 748
• Main Authors: Shea, Thomas C., Beaven, Anne W., Moore, Dominic T., Serody, Jonathan S., Gabriel, Don A., Chao, Nelson, Gockerman, Jon P., Garcia, Reynaldo A., Rizzieri, David A.
• Format: Journal Article
• Language: English
• Published: United States Informa UK Ltd 01-01-2009; Taylor & Francis
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - toxicity; Carboplatin - administration & dosage; chemotherapeutic approaches; Etoposide - administration & dosage; Feasibility Studies; Female; Hodgkin Disease - complications; Hodgkin Disease - drug therapy; Hodgkin Disease - mortality; Hodgkin Disease - therapy; Humans; Ifosfamide - administration & dosage; lymphoma and Hodgkin disease; Lymphoma, B-Cell - complications; Lymphoma, B-Cell - drug therapy; Lymphoma, B-Cell - mortality; Lymphoma, B-Cell - therapy; Male; Middle Aged; Neutropenia - chemically induced; Peripheral Blood Stem Cell Transplantation; Pharmacotherapeutics; Remission Induction; Salvage Therapy - methods; Survival Analysis; Thrombocytopenia - chemically induced; Transplantation, Autologous; Young Adult
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428190902853136

Non-cross resistant drugs given at high-dose intensity may maximise tumor cell kill leading to improved patient outcomes. We investigated the feasibility and efficacy of administering ifosfamide, carboplatin and etoposide ± rituximab as sequential high-dose single agents. Twenty-two patients with relapsed refractory Hodgkin lymphoma (n = 9) or non-Hodgkin (n = 13) lymphoma (NHL) were included. Therapy included: cycle 1 ifosfamide (15 g m2), cycle 2 etoposide (900 mg m2) and cycle 3 carboplatin (area under the curve 15). Patients with NHL received rituximab (375 mg m2) with cycles 1 and 2. Blood stem cell collection was performed after etoposide. Primary endpoints were overall response (complete response (CR) + PR) and ability to mobilise stem cells after etoposide. Secondary endpoints were to assess the toxicity of the regimen and to evaluate the ability of patients to proceed to stem cell transplant (SCT). Overall response rate was 54% with CR in 4 22 (18%) subjects and PR in 8 22 (36%). Median progression-free survival was 15 months and overall survival has not been reached at 40 months. Thirteen participants proceeded to SCT. Grade 3 4 thrombocytopenia and neutropenia occurred in 58% of cycles and 91% of subjects respectively. Forty-five percent of patients required hospitalisation for toxicity and two patients died from complications of therapy. Sequential dose intense ifosfamide, etoposide, carboplatin ± rituximab was more toxic and no more effective than the same drugs given in a conventional fashion.